Literature DB >> 19190916

Aperistaltic effect of hyoscine N-butylbromide versus glucagon on the small bowel assessed by magnetic resonance imaging.

Johannes M Froehlich1, Muriel Daenzer, Constantin von Weymarn, S Mehmet Erturk, Christoph L Zollikofer, Michael A Patak.   

Abstract

The aim of this prospective study was to compare the intraindividual aperistaltic effect of 40 mg hyoscine N-butylbromide (HBB/Buscopan) with that of 1 mg glucagon on small bowel motility by using magnetic resonance imaging (MRI). Ten healthy volunteers underwent two separate 1.5-T MRI studies (HBB/glucagon) after a standardized oral preparation with an aqueous solution of Gd-DOTA and ispaghula (Metamucil). A 2D T1-w GRE sequence was acquired (TR 2.7 ms/TE 1.3 ms, temporal resolution 0.25 s) before and after intravenous (i.v.) drug administration and motility was followed over 1 h. On the resulting images the cross-sectional luminal diameters were assessed and plotted over time. Baseline motility frequency, onset of aperistalsis, duration of arrest, reappearance of motility and return to normal motility were analysed. Significant differences regarding reliability and duration of aperistalsis were observed. In the HBB group aperistalsis lasted a mean of 6.8 +/- 5.3 min compared with 18.3 +/- 7 min after glucagon (p < 0.0001). In 50% of cases HBB did not accomplish aperistalsis, whereas glucagon always succeeded (p = 0.05). There were no significant differences in terms of baseline and end frequencies for the onset of aperistalsis (22.2 +/- 37.5 s HBB/13.4 +/- 9.2 s glucagon, p = 0.1), nor for the return to normal motility. Arrest of small bowel motion is achieved more reliably and lasts significantly longer after i.v. administration of 1 mg glucagon compared with 40 mg HBB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190916     DOI: 10.1007/s00330-008-1293-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  17 in total

Review 1.  Small intestinal manometry.

Authors:  M B Hansen
Journal:  Physiol Res       Date:  2002       Impact factor: 1.881

2.  Non-invasive measurement of small-bowel motility by MRI after abdominal surgery.

Authors:  Michael A Patak; Johannes M Froehlich; Constantin von Weymarn; Stefan Breitenstein; Christoph L Zollikofer; Klaus-Ulrich Wentz
Journal:  Gut       Date:  2007-07       Impact factor: 23.059

3.  Small bowel motility assessment with magnetic resonance imaging.

Authors:  Johannes M Froehlich; Michael A Patak; Constantin von Weymarn; Christoph F Juli; Christoph L Zollikofer; Klaus-Ulrich Wentz
Journal:  J Magn Reson Imaging       Date:  2005-04       Impact factor: 4.813

4.  The value of hyoscine butylbromide in abdominal MR imaging with and without oral magnetic particles.

Authors:  M Laniado; E Grönewäller; A F Kopp; S F Kaminsky; B Hamm; T F Jacobsen; C D Claussen
Journal:  Abdom Imaging       Date:  1997 Jul-Aug

5.  Compared effect of a genetically engineered glucagon and hyoscine N-butylbromide on double-contrast barium meal study.

Authors:  G Cittadini; F Sardanelli; E De Cicco; M Casiglia; T De Cata; R C Parodi
Journal:  Eur Radiol       Date:  1998       Impact factor: 5.315

6.  Effect of subcutaneous butylscopolamine administration in the reduction of peristaltic artifacts in 1.5-T MR fast abdominal examinations.

Authors:  Rosa Dosdá; Luis Martí-Bonmatí; Crisanto L Ronchera-Oms; Enrique Mollá; Estanislao Arana
Journal:  Eur Radiol       Date:  2002-06-21       Impact factor: 5.315

Review 7.  International Union of Pharmacology. XXXV. The glucagon receptor family.

Authors:  Kelly E Mayo; Laurence J Miller; Dominique Bataille; Stéphane Dalle; Burkhard Göke; Bernard Thorens; Daniel J Drucker
Journal:  Pharmacol Rev       Date:  2003-03       Impact factor: 25.468

8.  Reduction of bowel motion artifact during digital subtraction angiography: a comparison of hyoscine butylbromide and glucagon.

Authors:  R I Kozak; J D Bennett; T C Brown; T Y Lee
Journal:  Can Assoc Radiol J       Date:  1994-06       Impact factor: 2.248

9.  Action and side effects of small doses of buscopan in gastroduodenal radiography. A prospective study in 300 patients.

Authors:  D N Hüpscher; O Dommerholt
Journal:  Diagn Imaging Clin Med       Date:  1984

10.  Radiographic features in patients with pulmonary manifestations of the acquired immune deficiency syndrome.

Authors:  C W Heron; A L Hine; A L Pozniak; C R Swinburn; N M Johnson
Journal:  Clin Radiol       Date:  1985-11       Impact factor: 2.350

View more
  18 in total

1.  Quantified terminal ileal motility during MR enterography as a potential biomarker of Crohn's disease activity: a preliminary study.

Authors:  Alex Menys; David Atkinson; Freddy Odille; Asia Ahmed; Marco Novelli; Manuel Rodriguez-Justo; Ian Proctor; Shonit Punwani; Steve Halligan; Stuart A Taylor
Journal:  Eur Radiol       Date:  2012-06-03       Impact factor: 5.315

2.  MR motility imaging in Crohn's disease improves lesion detection compared with standard MR imaging.

Authors:  Johannes M Froehlich; Christian Waldherr; Christoforos Stoupis; S Mehmet Erturk; Michael A Patak
Journal:  Eur Radiol       Date:  2010-04-09       Impact factor: 5.315

3.  Indeterminate adnexal masses at ultrasound: effect of MRI imaging findings on diagnostic thinking and therapeutic decisions.

Authors:  Bianka Chilla; Nik Hauser; Gad Singer; Mafalda Trippel; Johannes M Froehlich; Rahel A Kubik-Huch
Journal:  Eur Radiol       Date:  2010-12-21       Impact factor: 5.315

4.  Evaluation of the anti-peristaltic effect of glucagon and hyoscine on the small bowel: comparison of intravenous and intramuscular drug administration.

Authors:  Andreas Gutzeit; Christoph A Binkert; Dow-Mu Koh; Klaus Hergan; Constantin von Weymarn; Nicole Graf; Michael A Patak; Justus E Roos; Marcus Horstmann; Sebastian Kos; Simone Hungerbühler; Johannes M Froehlich
Journal:  Eur Radiol       Date:  2012-01-22       Impact factor: 5.315

5.  Small bowel obstruction following computed tomography and magnetic resonance enterography using psyllium seed husk as an oral contrast agent.

Authors:  Yingming Amy Chen; Patrick Cervini; Anish Kirpalani; Paraskevi A Vlachou; Samir C Grover; Errol Colak
Journal:  Can J Gastroenterol Hepatol       Date:  2014 Jul-Aug

Review 6.  The clinical value of secretin-enhanced MRCP in the functional and morphological assessment of pancreatic diseases.

Authors:  Bella Chamokova; Nina Bastati; Sarah Poetter-Lang; Yesim Bican; Jacqueline C Hodge; Martin Schindl; Celso Matos; Ahmed Ba-Ssalamah
Journal:  Br J Radiol       Date:  2018-02-05       Impact factor: 3.039

7.  Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate.

Authors:  T Ullrich; M Quentin; A K Schmaltz; C Arsov; C Rubbert; D Blondin; R Rabenalt; P Albers; G Antoch; L Schimmöller
Journal:  Eur Radiol       Date:  2017-07-07       Impact factor: 5.315

Review 8.  MRI for the diagnosis and staging of deeply infiltrating endometriosis: a national survey of BSGE accredited endometriosis centres and review of the literature.

Authors:  Marianne Wild; Shikha Pandhi; John Rendle; Ian Swift; Emmanuel Ofuasia
Journal:  Br J Radiol       Date:  2020-07-30       Impact factor: 3.039

Review 9.  Magnetic resonance imaging in children and adolescents with chronic inflammatory bowel disease.

Authors:  Hans-Joachim Mentzel; Steffen Reinsch; Monika Kurzai; Martin Stenzel
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 10.  How we do it: MR enterography.

Authors:  Mary-Louise C Greer
Journal:  Pediatr Radiol       Date:  2016-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.